Statins in older adults

Australian Prescriber

Volumn 36, Issue 3, 2013, Pages 79-82

  Hilmer, Sarah ^a,b   Gnjidic, Danijela ^a,b,c,d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Ageing; Deprescribing; HMG CoA reductase inhibitors; Myopathy

Indexed keywords

AMIODARONE; ATORVASTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PLACEBO; SIMVASTATIN; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; AGING; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; FATIGUE; FRAIL ELDERLY; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GRIP STRENGTH; HUMAN; HYPOTHYROIDISM; INSTITUTIONALIZATION; KIDNEY DYSFUNCTION; LIFESPAN; LIVER DYSFUNCTION; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POLYPHARMACY; PRIMARY PREVENTION; RECURRENT DISEASE; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; WEIGHT REDUCTION;

EID: 84878508387     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2013.034     Document Type: Article

References (19)

1. Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012;196:50-3.
2. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993;153:1065-73.
3. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39.
4. Afilalo J, Duque G, Steele R, Jukema JW, De Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian metaanalysis. J Am Coll Cardiol 2008;51:37-45.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
6. Lacroix AZ, Gray SL, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 2008;63:369-75.
7. Gnjidic D, Le Couteur DG, Blyth FM, Travison T, Rogers K, Naganathan V, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 2013;3:e002333.
8. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009;2:CD003160.
9. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010;8:CD007514.
10. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012;10:296-302.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
12. Zhou Z, Rahme E, Abrahamowicz M, Tu JV, Eisenberg MJ, Humphries K, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005;172:1187-94.
13. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8.
14. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42.
15. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11.
16. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23:1663-7.
17. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80.
18. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-2.
19. Smith J. Appropriate primary prevention of cardiovascular disease: Does this mean more or less statin use? Aust Prescr 2011;34:169-72.